FOLH1 and metastatic prostate carcinoma: PSMA-PET has a lot of evidence for primary staging evaluation in localized intermediate- and high-risk prostate cancer and diagnosis of biochemical recurrence (BCR) after radical prostatectomy (RP) or radiotherapy, but there are many challenges for diagnosis in metastatic prostate cancer and CRPC.